Celldex Therapeutics (CLDX)
(Real Time Quote from BATS)
$37.17 USD
-0.60 (-1.59%)
Updated Apr 24, 2024 02:28 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Celldex Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 424 | 305 | 408 | 194 | 64 |
Receivables | 3 | 0 | 0 | 2 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 12 | 2 | 2 | 1 |
Total Current Assets | 432 | 318 | 411 | 198 | 67 |
Net Property & Equipment | 4 | 4 | 4 | 4 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 27 | 27 | 27 | 31 | 49 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 466 | 353 | 445 | 236 | 123 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 22 | 13 | 12 | 8 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 1 | 2 | 3 | 2 |
Total Current Liabilities | 31 | 19 | 17 | 14 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 3 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 5 | 7 | 10 | 16 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 36 | 27 | 25 | 26 | 29 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,823 | 1,581 | 1,561 | 1,280 | 1,105 |
Retained Earnings | -1,397 | -1,256 | -1,144 | -1,073 | -1,013 |
Other Equity | 3 | 1 | 2 | 3 | 3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 429 | 326 | 419 | 209 | 94 |
Total Liabilities & Shareholder's Equity | 466 | 353 | 445 | 236 | 123 |
Total Common Equity | 429 | 326 | 419 | 209 | 94 |
Shares Outstanding | 47.20 | 47.10 | 46.60 | 39.50 | 16.10 |
Book Value Per Share | 9.09 | 6.93 | 9.00 | 5.30 | 5.84 |
Fiscal Year End for Celldex Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 424 | 235 | 253 | 278 |
Receivables | NA | 3 | 0 | 0 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 5 | 10 | 12 | 10 |
Total Current Assets | NA | 432 | 246 | 265 | 290 |
Net Property & Equipment | NA | 4 | 4 | 4 | 4 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 27 | 27 | 27 | 27 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 466 | 280 | 299 | 325 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 4 | 1 | 3 |
Current Portion Long-Term Debt | NA | 0 | 4 | 1 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 22 | 18 | 12 | 9 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 4 | 0 | 0 | 1 |
Total Current Liabilities | NA | 31 | 28 | 16 | 15 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 4 | 4 | 4 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 36 | 34 | 22 | 22 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,823 | 1,599 | 1,591 | 1,586 |
Retained Earnings | NA | -1,397 | -1,354 | -1,316 | -1,285 |
Other Equity | NA | 3 | 2 | 2 | 2 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 429 | 247 | 278 | 303 |
Total Liabilities & Shareholder's Equity | NA | 466 | 280 | 299 | 325 |
Total Common Equity | 0 | 429 | 247 | 278 | 303 |
Shares Outstanding | 55.90 | 47.20 | 47.20 | 47.20 | 47.20 |
Book Value Per Share | 0.00 | 9.09 | 5.23 | 5.88 | 6.41 |